NovaBay Net Income Per E B T from 2010 to 2024

NBY Stock  USD 0.53  0.04  8.16%   
NovaBay Pharmaceuticals Net Income Per E B T yearly trend continues to be fairly stable with very little volatility. Net Income Per E B T will likely drop to 0.84 in 2024. During the period from 2010 to 2024, NovaBay Pharmaceuticals Net Income Per E B T regression line of annual values had r-squared of  0.17 and arithmetic mean of  1.06. View All Fundamentals
 
Net Income Per E B T  
First Reported
2010-12-31
Previous Quarter
1.38
Current Value
0.84
Quarterly Volatility
0.17216288
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check NovaBay Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among NovaBay Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 229.5 K, Interest Expense of 4.6 M or Other Operating Expenses of 16.9 M, as well as many indicators such as Price To Sales Ratio of 0.0555, Dividend Yield of 0.0 or PTB Ratio of 0.25. NovaBay financial statements analysis is a perfect complement when working with NovaBay Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of NovaBay Pharmaceuticals Correlation against competitors.
For more information on how to buy NovaBay Stock please use our How to Invest in NovaBay Pharmaceuticals guide.

Latest NovaBay Pharmaceuticals' Net Income Per E B T Growth Pattern

Below is the plot of the Net Income Per E B T of NovaBay Pharmaceuticals over the last few years. It is NovaBay Pharmaceuticals' Net Income Per E B T historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in NovaBay Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Net Income Per E B T10 Years Trend
Slightly volatile
   Net Income Per E B T   
       Timeline  

NovaBay Net Income Per E B T Regression Statistics

Arithmetic Mean1.06
Geometric Mean1.05
Coefficient Of Variation16.17
Mean Deviation0.12
Median1.00
Standard Deviation0.17
Sample Variance0.03
Range0.6933
R-Value0.42
Mean Square Error0.03
R-Squared0.17
Significance0.12
Slope0.02
Total Sum of Squares0.41

NovaBay Net Income Per E B T History

2024 0.84
2023 1.38
2022 1.53
2021 1.13
2019 1.09

About NovaBay Pharmaceuticals Financial Statements

NovaBay Pharmaceuticals investors use historical fundamental indicators, such as NovaBay Pharmaceuticals' Net Income Per E B T, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in NovaBay Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Income Per E B T 1.38  0.84 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for NovaBay Stock Analysis

When running NovaBay Pharmaceuticals' price analysis, check to measure NovaBay Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NovaBay Pharmaceuticals is operating at the current time. Most of NovaBay Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of NovaBay Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NovaBay Pharmaceuticals' price. Additionally, you may evaluate how the addition of NovaBay Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.